Amgen Inc.

Maya C Thaman

Celia Dominguez

Matthew W Martin

Craig E Masse

Andrew Stewart Tasker

Joseph L Kim

Jean-Christophe P Harmange

Brian K Albrecht

Vinod Francis Patel

Jean E Bemis

Brian Lewis Hodous

Anthony B Reed

Robert Michael Rzasa

Ryan D White

Victor J Cee

Kelvin K C Sham

Liping H Pettus

Dawei Zhang

Shimin Xu

Steven F Bellon

Russell Graceffa

James Richard Falsey

Randall W Hungate

Erin F DiMauro

Adrian Leonard Smith

Paul A Tempest

Stuart C Chaffee

Philip R Olivieri

Gregory J Habgood

Nick A Paras

Bradley J Herberich

Holly L Deak

Guo-Qiang Cao

Partha P Chakrabarti

William H Buckner

Kelvin Sham

Partha Pratim Chakrabarti

Kelvin KC Sham

David C Mcgowan

Susan Ann Tomlinson

Frenel F Demorin

Guo-Giang Cao

John L Buchanan

Erin F Dimauro

Stephanie D Geuns-Meyer

Stephanie D Geuns-meyer

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein B, R, R, R, Rand Rare d.efined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Phthalazine compounds and methods of use

The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T -cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs.

Substituted heterocyclic compounds and methods of use

Growing community of inventors

Ventura, CA, United States of America

Maya C Thaman